Health Trials

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

ConditionMultiple Myeloma
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorPfizer

About this trial

This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.

Eligibility criteria

Qualifiers

Participants must agree to follow the reproductive criteria as outlined in the protocol

Participants have completed a qualifying Parent Study, were still receiving elranatamab when the Parent Study terminated or completed, and are deriving clinical benefit from elranatamab (as determined by the investigator).

Disqualifiers

Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.

Participants not previously enrolled or who have discontinued study treatment in a Parent Study are ineligible for participation in this study.

Trial design

Treatments tested in this trial

  • Elranatamab

Treatment groups

80 Participants
are divided into 1 treatment group

Locations

33
Australia
Epworth Freemasons3002, MelbourneVictoria, Australia
Epworth Hospital3121, RichmondVictoria, Australia
Slade Pharmacy3121, RichmondVictoria, Australia
Canada
Arthur J.E. Child Comprehensive Cancer CentreT2N 5GN, CalgaryAlberta, Canada

Sponsors and collaborators

Pfizer

Lead sponsor

Source ClinicalTrials.gov